Polycystic ovary syndrome (PCOS) is a common
hormonal disorder in women of reproductive age, characterized by chronic
inflammation, elevated oxidative stress, and abnormalities in cell death
mechanisms (apoptosis). These biological imbalances contribute to issues such
as irregular ovulation, hormonal disturbances, and other PCOS symptoms.
In this
context, astaxanthin (ASX), a potent antioxidant, is being investigated for its
potential to reduce inflammation and improve cellular function by modulating endoplasmic
reticulum stress and apoptosis. These effects may enhance ovarian function and
provide new therapeutic avenues for women with PCOS.
What are the effects of astaxanthin on
inflammation and cellular stress in PCOS?
This study involved 56 women with PCOS, divided into two groups:
- ASX Group: 12 mg of astaxanthin daily.
- Placebo
Group.
Over eight weeks, the study aimed to evaluate
the impact of ASX on inflammatory markers (TNF-α, IL-18, IL-6, CRP) and the
expression of genes related to endoplasmic reticulum stress and apoptosis in
peripheral blood mononuclear cells (PBMCs).
Key findings include:
- Reduction
in inflammatory markers:
The ASX group showed a significant decrease in TNF-α, IL-18, and IL-6
levels compared to the placebo group. No significant change was observed
for CRP.
- Impact on
endoplasmic reticulum stress: ASX reduced the expression of several genes associated with
endoplasmic reticulum stress, such as CHOP, ATF4, XBP1, and DR5,
indicating improved cellular stress regulation.
- No
significant improvement in clinical symptoms: Despite positive biological effects, no
significant changes were observed in clinical symptoms such as hirsutism,
hair loss, or menstrual cycle regularity.
Astaxanthin: a hopeful ally against
inflammation in PCOS
The findings suggest that ASX may have a beneficial role in modulating
inflammatory and apoptotic processes in women with PCOS. However, while these
effects highlight a potential pathway for addressing the biological symptoms of
the condition, no significant clinical improvements were observed.
These
results emphasize the need for further research, particularly on dosage and
treatment duration, to confirm the efficacy of ASX in managing PCOS.
